{"id":6365,"date":"2022-04-28T10:55:00","date_gmt":"2022-04-28T10:55:00","guid":{"rendered":"https:\/\/nanexa.com\/mfn_news\/europeiska-patentverket-har-godkant-nanexas-pharmashell-patent\/"},"modified":"2022-04-28T10:55:00","modified_gmt":"2022-04-28T10:55:00","slug":"europeiska-patentverket-har-godkant-nanexas-pharmashell-patent","status":"publish","type":"mfn_news","link":"https:\/\/nanexa.com\/sv\/mfn_news\/europeiska-patentverket-har-godkant-nanexas-pharmashell-patent\/","title":{"rendered":"Europeiska patentverket har godk\u00e4nt Nanexas PharmaShell\u00ae-patent"},"content":{"rendered":"<div class=\"mfn-preamble\">\n<p><strong>Nanexa AB (publ) meddelar idag att det europeiska patentverket (EPO) har godk\u00e4nt bolagets patentans\u00f6kan avseende drug delivery-systemet PharmaShell\u00ae. Patentskyddet omfattar metoden f\u00f6r tillverkning av PharmaShell och produkter tillverkade genom metoden.<\/strong><\/p>\n<\/div>\n<div class=\"mfn-body\">\n<p>\u201dV\u00e4gen till godk\u00e4nd patentans\u00f6kan kan vara l\u00e5ng och vi har jobbat h\u00e5rt i v\u00e5ra diskussioner med EPO f\u00f6r att f\u00e5 igenom ett s\u00e5 starkt europeiskt patentskydd som m\u00f6jligt. Det \u00e4r med stor tillfredsst\u00e4llelse jag nu kan konstatera att PharmaShell-patentet \u00e4r godk\u00e4nt i Europa. Vi har hela tiden k\u00e4nt oss trygga i v\u00e5r patentsituation men det betyder \u00e4nd\u00e5 mycket att f\u00e5 det bekr\u00e4ftat av EPO. Nu n\u00e4r vi har detta patent godk\u00e4nt hamnar vi i en \u00e4n mer intressant position i diskussioner med potentiella partners.\u201d, s\u00e4ger David Westberg, vd f\u00f6r Nanexa.<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-contacts\">\n<p><strong class=\"mfn-heading-1\">F\u00f6r mer information kontakta:<\/strong><\/p>\n<hr\/>\n<p>David Westberg \u2013 VD, Nanexa AB (publ)\u00a0<br \/>Telefon: 0709-42 83 03<br \/>E-post:\u00a0<a href=\"mailto:david.westberg@nanexa.se\" target=\"_blank\" rel=\"nofollow noopener\">david.westberg@nanexa.se<\/a><br \/><a target=\"_blank\" href=\"http:\/\/www.nanexa.com\" rel=\"nofollow noopener\">www.nanexa.com<\/a><\/p>\n<p>Erik Penser Bank \u00e4r bolagets Certified Adviser och n\u00e5s p\u00e5 08-463 83 00, e-post: certifiedadviser@penser.se<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-about\">\n<p><strong class=\"mfn-heading-1\">Om Nanexa AB (publ)<\/strong><\/p>\n<hr\/>\n<p>Nanexa \u00e4r ett l\u00e4kemedelsbolag som utvecklar parenterala l\u00e4kemedel baserade p\u00e5 det patenterade och innovativa drug delivery-systemet PharmaShell\u00ae \u2013 ett system som m\u00f6jligg\u00f6r n\u00e4sta generations l\u00e5ngverkande injicerbara l\u00e4kemedel med h\u00f6g drug load, tillverkade med atomlagerprecision. Nanexa utvecklar egna produkter och har dessutom samarbetsavtal med flera l\u00e4kemedelsbolag, d\u00e4ribland AstraZeneca.<\/p>\n<p>Nanexas aktie \u00e4r noterad p\u00e5 Nasdaq First North Growth Market i Stockholm (NANEXA).<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-attachment mfn-attachment-general\">\n<p><strong class=\"mfn-heading-1\">Bifogade filer<\/strong><\/p>\n<hr\/>\n<p><a class=\"mfn-generated mfn-primary\" href=\"https:\/\/storage.mfn.se\/5c7f91a0-7f10-4900-a393-7fc50765fd39\/europeiska-patentverket-har-godkant-nanexas-pharmashell-r-patent.pdf\" target=\"_blank\" rel=\"nofollow noopener\">Europeiska patentverket har godk\u00e4nt Nanexas PharmaShell\u00ae-patent<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Nanexa AB (publ) meddelar idag att det europeiska patentverket (EPO) har godk\u00e4nt bolagets patentans\u00f6kan avseende drug delivery-systemet PharmaShell\u00ae. Patentskyddet omfattar metoden f\u00f6r tillverkning av PharmaShell och produkter tillverkade genom metoden.<\/p>\n","protected":false},"template":"","class_list":["post-6365","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-ci_sv","mfn-news-tag-mfn-type-ir_sv","mfn-news-tag-mfn_sv","mfn-news-tag-mfn-ci-other_sv","mfn-news-tag-mfn-lang-sv_sv"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Europeiska patentverket har godk\u00e4nt Nanexas PharmaShell\u00ae-patent - Nanexa AB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanexa.com\/mfn_news\/europeiska-patentverket-har-godkant-nanexas-pharmashell-patent\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Europeiska patentverket har godk\u00e4nt Nanexas PharmaShell\u00ae-patent - Nanexa AB\" \/>\n<meta property=\"og:description\" content=\"Nanexa AB (publ) meddelar idag att det europeiska patentverket (EPO) har godk\u00e4nt bolagets patentans\u00f6kan avseende drug delivery-systemet PharmaShell\u00ae. Patentskyddet omfattar metoden f\u00f6r tillverkning av PharmaShell och produkter tillverkade genom metoden.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanexa.com\/mfn_news\/europeiska-patentverket-har-godkant-nanexas-pharmashell-patent\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanexa AB\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minut\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/europeiska-patentverket-har-godkant-nanexas-pharmashell-patent\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/europeiska-patentverket-har-godkant-nanexas-pharmashell-patent\\\/\",\"name\":\"Europeiska patentverket har godk\u00e4nt Nanexas PharmaShell\u00ae-patent - Nanexa AB\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\"},\"datePublished\":\"2022-04-28T10:55:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/europeiska-patentverket-har-godkant-nanexas-pharmashell-patent\\\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/europeiska-patentverket-har-godkant-nanexas-pharmashell-patent\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/europeiska-patentverket-har-godkant-nanexas-pharmashell-patent\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Hem\",\"item\":\"https:\\\/\\\/nanexa.com\\\/sv\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN News Items\",\"item\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Europeiska patentverket har godk\u00e4nt Nanexas PharmaShell\u00ae-patent\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"name\":\"Nanexa AB\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanexa.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\",\"name\":\"Nanexa AB\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"sv-SE\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"contentUrl\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"width\":165,\"height\":50,\"caption\":\"Nanexa AB\"},\"image\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Europeiska patentverket har godk\u00e4nt Nanexas PharmaShell\u00ae-patent - Nanexa AB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanexa.com\/mfn_news\/europeiska-patentverket-har-godkant-nanexas-pharmashell-patent\/","og_locale":"sv_SE","og_type":"article","og_title":"Europeiska patentverket har godk\u00e4nt Nanexas PharmaShell\u00ae-patent - Nanexa AB","og_description":"Nanexa AB (publ) meddelar idag att det europeiska patentverket (EPO) har godk\u00e4nt bolagets patentans\u00f6kan avseende drug delivery-systemet PharmaShell\u00ae. Patentskyddet omfattar metoden f\u00f6r tillverkning av PharmaShell och produkter tillverkade genom metoden.","og_url":"https:\/\/nanexa.com\/mfn_news\/europeiska-patentverket-har-godkant-nanexas-pharmashell-patent\/","og_site_name":"Nanexa AB","twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"1 minut"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/nanexa.com\/mfn_news\/europeiska-patentverket-har-godkant-nanexas-pharmashell-patent\/","url":"https:\/\/nanexa.com\/mfn_news\/europeiska-patentverket-har-godkant-nanexas-pharmashell-patent\/","name":"Europeiska patentverket har godk\u00e4nt Nanexas PharmaShell\u00ae-patent - Nanexa AB","isPartOf":{"@id":"https:\/\/nanexa.com\/#website"},"datePublished":"2022-04-28T10:55:00+00:00","breadcrumb":{"@id":"https:\/\/nanexa.com\/mfn_news\/europeiska-patentverket-har-godkant-nanexas-pharmashell-patent\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanexa.com\/mfn_news\/europeiska-patentverket-har-godkant-nanexas-pharmashell-patent\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/nanexa.com\/mfn_news\/europeiska-patentverket-har-godkant-nanexas-pharmashell-patent\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Hem","item":"https:\/\/nanexa.com\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN News Items","item":"https:\/\/nanexa.com\/mfn_news\/"},{"@type":"ListItem","position":3,"name":"Europeiska patentverket har godk\u00e4nt Nanexas PharmaShell\u00ae-patent"}]},{"@type":"WebSite","@id":"https:\/\/nanexa.com\/#website","url":"https:\/\/nanexa.com\/","name":"Nanexa AB","description":"","publisher":{"@id":"https:\/\/nanexa.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanexa.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"},{"@type":"Organization","@id":"https:\/\/nanexa.com\/#organization","name":"Nanexa AB","url":"https:\/\/nanexa.com\/","logo":{"@type":"ImageObject","inLanguage":"sv-SE","@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","contentUrl":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","width":165,"height":50,"caption":"Nanexa AB"},"image":{"@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news\/6365","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/media?parent=6365"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}